Keytruda Poised To Add Early TNBC To Its Resumé As KEYNOTE-522 Hits First Endpoint
Executive Summary
A first look at data from Merck & Co’s KEYNOTE-522 trial of Keytruda in early triple-negative breast cancer showed significant pathological response rates and hinted at good things to come in event-free survival, but experts at ESMO want more mature data.
You may also be interested in...
Merck & Co.’s Keytruda Gets Fighting Chance In TNBC
The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.
Keytruda Closing In On First-Line Metastatic Triple-Negative Breast Cancer
An interim analysis of the Phase III KEYNOTE-355 study in triple-negative breast cancer patients reports that first-line pembrolizumab combined with chemotherapy has met the PFS primary endpoint, but Merck & Co is still a long way behind Roche’s Tecentriq in the additional indication.
Eight Talking Points From ESMO
Proving once again that it is a match for ASCO, here are highlights from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona from 27 September to 1 October.